Redeye initiates coverage of AroCell

Report this content

We initiate coverage of AroCell, a diagnostics company that focuses on the research, development and sales of an in vitro diagnostics product for cancer, called TK 210 ELISA, and the licensing of the technology behind this. After several years focusing on research and development, AroCell is now switching over to a commercial focus with itsTK 1 technology for cancer therapy response analysis. We see several potential catalysts in the short- and mid-term that are positive for the stock.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.